Adelmidrol PPAR-Gamma Agonist Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for articular chondropathies, inflammatory bowel diseases, and systemic sclerosis lack specific agonists for the PPAR-gamma receptor, leading to inadequate protection of cartilage and exacerbation of degenerative processes.
Innovation Solution
Adelmidrol, a derivative of azelaic acid diethanolamide, acts as a specific agonist of the PPAR-gamma receptor, effectively reducing inflammation and fibrosis in articular cartilage, bowel tissues, and lung tissues, thereby providing therapeutic benefits for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic agonists of PPAR-gamma are used to treat articular chondropathies, then cartilage protection is improved, but side effects and non-specific effects increase
Solution Approach 1:
The patent modifies the chemical structure of PPAR-gamma agonists by introducing specific substituents (R1, R2, R3, R4 groups) to create derivatives with improved selectivity. This structural parameter change allows the compound to maintain agonist activity while reducing non-specific effects and side effects through more precise receptor interaction.
Solution Approach 2:
The invention introduces specific local modifications to the agonist molecule at particular positions (indicated by R1-R4 substituents), creating localized changes in molecular properties that enhance selectivity for the PPAR-gamma receptor while minimizing interactions with other biological targets, thereby reducing side effects.
2Object-affected harmful factors
If PPAR-gamma agonists are used to treat inflammatory processes, then inflammation reduction is improved, but specificity of action decreases
Solution Approach 1:
The patent employs systematic variation of molecular parameters (substituent groups R1-R4) to optimize the agonist's specificity profile, enabling selective anti-inflammatory action through the PPAR-gamma pathway while minimizing off-target effects on other inflammatory mediators or receptors.
Solution Approach 2:
The modified agonist acts as a selective intermediary that specifically activates the PPAR-gamma receptor to mediate anti-inflammatory effects, rather than broadly suppressing inflammation through multiple non-specific pathways, thereby achieving targeted therapeutic action.
Data Source
AI summary
Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.